...Welcome back, everybody, to the next session at the SVB Leerink Healthcare Conference, I'm Marc Goodman, one of the biopharma analysts. And we're lucky enough to have Avadel join us. And we have their CEO, Greg Divis, who's been CEO for the past few years. And obviously, this is a company where -- they have one product that is at FDA and everybody is eagerly waiting for this approval or to hear what's going on. And so, Greg, I guess you got to start with that. So I'll give you some time for opening comments, but you got to tell us where we are and what's happening. Gregory J. Divis ...